The expanding role of rituximab and radioimmunotherapy in the treatment of B-cell lymphomas

Bibliography

• PARKER SL, TONG T, BOLDEN S, WINGO PA: Cancer statistics, 1996. CA Cancer J. Clin. (1996) 46(1):5-27.
   Google Scholar
• MÜLLER AMS, IHORST G, MERTELSMANN R, ENGELHARDT M: Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology. Ann. Hematol. (2005) 84:1-12.
   PubMed Web of Science ®Google Scholar
• AISENBERG AC: Coherent view of non-Hodgkin's lymphoma. J. Clin. Oncol. (1995) 13(10):2656-2675.
   PubMed Web of Science ®Google Scholar
• EDWARDS BK, BROWN ML, WINGO PA et al.: Annual report to the nation on the status of cancer, 1975 – 2002, featuring population-based trends in cancer treatment. J. Natl. Cancer Inst. (2005) 97(19):1407-1427.
   PubMed Web of Science ®Google Scholar
• WORLD HEALTH ORGANIZATION: Classification of tumours, pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon, France (2001).
   Google Scholar
• CARTRON G, WATIER H, GOLAY J, SOLAL-CELIGNY P: From the bench to the bedside: ways to improve rituximab efficacy. Blood (2004) 104:2635-2642.
   PubMed Web of Science ®Google Scholar
• GOLAY JT, CLARK EA, BEVERLEY PC: The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle. J. Immunol. (1985) 135:3795-3801.
   PubMed Web of Science ®Google Scholar
• IDEC PHARMACEUTICALS: Yttrium-[90] ibritumomab tiuxetan (Zevalin™; IDEC-Y2B8) radioimmunotherapy regimen. Investigational Brochure. 6th Edition (2001).
   Google Scholar
• REFF ME, CARNER K, CHAMBERS KS et al.: Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood (1994) 83:435-445.
   PubMed Web of Science ®Google Scholar
• GOLAY J, LAZZARI M, FACCHINETTI V et al.: CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood (2001) 98:3383-3389.
   PubMed Web of Science ®Google Scholar
• GOLAY J, ZAFFARONI L, VACCARI T et al.: Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood (2000) 95:3900-3908.
   PubMed Web of Science ®Google Scholar
• TREON SP, MITSIADES C, MITSIADES N et al.: Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. J. Immunother. (2001) 24(3):263-271.
   PubMed Web of Science ®Google Scholar
• CARTRON G, DACHEAUX L, SALLES G et al.: Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FeYRIIIa gene. Blood (2002) 99:754-758.
   PubMed Web of Science ®Google Scholar
• WENG WK, LEVY R: Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. (2003) 21:3940-3947.
   PubMed Web of Science ®Google Scholar
• WENG WK, LEVY R: Rituximab-induced antibody-dependent cellular cytotoxicity (ADCC) in vollicular non-Hodgkin's lymphoma. Blood (2002) 100 (Abstract).
   Google Scholar
• KAUFMANN H, RAFIQ K, WOHRER S et al.: Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood (2004) 104(8):2269-2271.
   PubMed Web of Science ®Google Scholar
• BONAVIDA B: Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene (2007) 26(25):3629-3636.
   PubMed Web of Science ®Google Scholar
• BYRD JC, KITADA S, FLINN IW et al.: The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evicence of caspase activation and apoptosis induction. Blood (2002) 99(3):1038-1043.
   PubMed Web of Science ®Google Scholar
• CHAN HT, HUGHES D, FRENCH RR et al.: CD20-induced lymphoma cell death is independent of both caspases and its redistribution into tritonX-100 insoluale membrane rafts. Cancer Res. (2003) 63(17):5480-5489.
   PubMed Web of Science ®Google Scholar
• VAN DER KOLK LE, EVERS LM, OMENE CL et al.: CD20-induced B cell death can bypass mitochondria and caspase activation. Leukemia (2002) 16(9):1735-1744.
   PubMed Web of Science ®Google Scholar
• KAMINSKI MS, ESTES J, ZASADNY KR et al.: Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood (2000) 96:1259-1266.
   PubMed Web of Science ®Google Scholar
• CHINN PC, LEONARD JE, ROSENBERG J, HANNA N, ANDERSON DR: Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma. Int. J. Oncol. (1999) 15:1017-1025.
   PubMed Web of Science ®Google Scholar
• JOHNSTON PB, BONDLY C, MICALLEF I: Ibritumomab tiuxetan for non-Hodgkin's lymphoma. Expert Rev. Anticancer Ther. (2006) 6(6):861-869.
   PubMed Web of Science ®Google Scholar
• WHITE CA: Radioimmunotherapy in non-Hodgkin's lymphoma: focus on 90Y-ibritumomab tiuxetan (Zevalin®). J. Exp. Ther. Oncol. (2004) 4:305-316.
   PubMedGoogle Scholar
• JACOBS SA, HARRISON AM, SWERDLOW SH et al.: Cellular localization pattern of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) in a patient with low-grade non-Hodgkin's lymphoma (NHL). Blood (2004) 104(11).
   Google Scholar
• LOSSOS IS, LEVY R: Higher-grade transformation of follicle center lymphoma is associated with somatic mutation of the 5′ noncoding regulatory region of the BCL-6 gene. Blood (2000) 96(2):635-639.
   PubMed Web of Science ®Google Scholar
• KORSMEYER SJ: Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood (1992) 80(4):879-886.
   PubMed Web of Science ®Google Scholar
• SOLAL-CÉLIGNY P, ROY P, COLOMBAT P et al.: Follicular lymphoma international prognostic index. Blood (2004) 104(5):1258-1265.
   PubMed Web of Science ®Google Scholar
• KÜPPERS R: Prognosis in follicular lymphoma – it's in the microenvironment. N. Engl. J. Med. (2004) 351(21):2152-2153.
   PubMed Web of Science ®Google Scholar
• DAVE SS, WRIGHT G, TAN B et al.: Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N. Engl. J. Med. (2004) 351(21):2159-2167.
   PubMed Web of Science ®Google Scholar
• FISHER RI, LEBLANC M, PRESS OW, MALONEY DG, UNGER JM, MILLER TP: New treatment options have changed the survival of patients with follicular lymphoma. J. Clin. Oncol. (2005) 23(33):8447-8452.
   PubMed Web of Science ®Google Scholar
• MALONEY DG, GRILLO-LOPEZ AJ, BODKIN DJ et al.: IDEC-C2B8: results of a Phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J. Clin. Oncol. (1997) 15(10):3266-3274.
   PubMed Web of Science ®Google Scholar
• MCLAUGHLIN P, GRILLO-LOPEZ AJ, LINK BK et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. (1998) 16(8):2825-2833.
   PubMed Web of Science ®Google Scholar
• COLOMBAT P, SALLES G, BROUSSE N et al.: Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood (2001) 97(1):101-106.
   PubMed Web of Science ®Google Scholar
• PIRO LD, WHITE CA, GRILLO-LOPEZ AJ et al.: Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann. Oncol. (1999) 10(6):655-661.
   PubMed Web of Science ®Google Scholar
• HAINSWORTH JD, LITCHY S, BURRIS HA III et al.: Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. J. Clin. Oncol. (2002) 20(20):4261-4267.
   PubMed Web of Science ®Google Scholar
• HAINSWORTH JD, BURRIS HA III, MORISSEY LH et al.: Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood (2000) 95(10):3052-3056.
   PubMed Web of Science ®Google Scholar
• GORDAN LN, GROW WB, PUSATERI A, DOUGLAS V, MENDENHALL NP, LYNCH JW: Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. J. Clin. Oncol. (2005) 23(6):1096-1102.
   PubMed Web of Science ®Google Scholar
• KAMINSKI MS, ESTES J, TUCK M, ROSS CW, WAHL RL: I131-tositumomab monotherapy as frontline treatment for follicular lymphoma: updated results after a median follow-up of 8 years. J. Clin. Oncol. (2007) 25(18S) (Abstract).
   Google Scholar
• KAMINSKI MS, TUCK M, ESTES J et al.: 131I-tositumomab therapy as initial treatment for follicular lymphoma. N. Engl. J. Med. (2005) 352:441-449.
   PubMed Web of Science ®Google Scholar
• CZUCZMAN M, GRILLO-LOPEZ AJ, MCLAUGHLIN P, WHITE CA: Clearing of cells bearing the bcl-2 [t(14; 18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy. Ann. Oncol. (2001) 12:109-114.
   PubMed Web of Science ®Google Scholar
• CZUCZMAN MS, WEAVER R, ALKUZWENY B, BERLFEIN J, GRILLO-LOPEZ AJ: Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J. Clin. Oncol. (2004) 22(23):4711-4716.
   PubMed Web of Science ®Google Scholar
• CZUCZMAN MS, KORYZNA A, MOHR A et al.: Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J. Clin. Oncol. (2005) 23(4):694-704.
   PubMed Web of Science ®Google Scholar
• FORSTPOINTNER R, DREYLING M, REPP R et al.: The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German low-grade lymphoma study group. Blood (2004) 104(10):3064-3071.
   PubMed Web of Science ®Google Scholar
• FORSTPOINTNER R, UNTERHALT M, DREYLING M et al.: Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle call lymphomas: results of a prospective randomized study of the Greman low grade lymphoma study group (GLSG). Blood (2006) 108(13):4003-4008.
   PubMed Web of Science ®Google Scholar
• HOCHSTER HS, WELLER E, RYAN T et al.: Results of E1496: A Phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL). J. Clin. Oncol. (2004) 22(14S) (Abstract).
   Google Scholar
• HOCHSTER HS, WELLER E, GASCOYNE RD et al.: Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): results of the E1496 Phase III trial from the Eastern cooperative oncology group and the cancer and leukemia group B. Blood (2005) 106(11):A106 (Abstract).
   Google Scholar
• MARCUS R, IMRIE K, BELCH A et al.: CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood (2005) 105(4):1417-1423.
   PubMed Web of Science ®Google Scholar
• HIDDEMANN W, KNEBA M, DREYLING M et al.: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German low-grade lymphoma study group. Blood (2005) 106(12):3725-3732.
   PubMed Web of Science ®Google Scholar
• PRESS OW, UNGER JM, BRAZIEL RM et al.: Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphomna: five-year follo-up of Southwest oncology group protocol S9911. J. Clin. Oncol. (2006) 24(25):4143-4149.
   PubMed Web of Science ®Google Scholar
• LEONARD JP, COLEMAN M, KOSTAKOBLU L et al.: Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J. Clin. Oncol. (2005) 23(24):5696-5704.
   PubMed Web of Science ®Google Scholar
• LINK B, KAMINSKI MS, COLEMAN M, LEONARD JP: Phase II study of CVP followed by tositumomab and iodine I 131 tositumomab (Bexxar therapeutic regimen) in patients with untreated follicular non-Hodgkin's lymphoma (NHL). J. Clin. Oncol. (2004) 22(14S) (Abstract).
   Google Scholar
• SHIPLEY DL, SPIGEL DR, CARRELL DL, DANNAHER C, GRECO FA, HAINSWORTH JD: Phase II trial of rituximab and short duration chemotherapy followed by 90Y-ibritumomab tiuxetan as first-line treatment for patients with follocular lymphoma: a minnie pearl cancer research network Phase II trial. J. Clin. Oncol. (2004) 22(14S) (Abstract).
   PubMedGoogle Scholar
• ZINZANI PL, PULSONI A, BALOCCO M et al.: A Phase II trial of FM (oral fludarabine and mitoxantrone) chemotherapy followed by yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) for previously untreated follicular lymphoma (FL) patients. Blood (2006) 108(11) (Abstract).
   Google Scholar
• JANKOWITZ RC, DEMONACO NA, FOON KA et al.: Phase II study of short course CHOP-rituximab (R) followed by ibritumomab tiuxetan (IT) as first-line treatment for follicular lymphoma (FL). J. Clin. Oncol. (2007) 25(18S) (Abstract).
   Google Scholar
• JUWEID ME, STROOBANTS S, HOEKSTRA OS et al.: Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of international harmonization project in lymphoma. J. Clin. Oncol. (2007) 25(5):571-578.
   PubMed Web of Science ®Google Scholar
• CHESON BD, PFISTNER B, JUWEID ME et al.: Revised response criteria for malignant lymphoma. J. Clin. Oncol. (2007) 25(5):579-586.
   PubMed Web of Science ®Google Scholar
• VAN OERS MHJ, KLASA R, MARCUS RE et al.: Rituximab maintenance improves clinical outcome of relapsed-resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized Phase II intergroup trial. Blood (2006) 108(10):3295-3301.
   PubMed Web of Science ®Google Scholar
• HARRIS NL, JAFFE ES, DIEBOLD J et al.: The World Health Organization classification of hematological malignancies report of the clinical advisory committee meeting. Airlie House, Virginia, November 1997. Mod. Pathol. (2000) 13(2):193-207.
   PubMed Web of Science ®Google Scholar
• MOLLEJO M, MENARGUEZ J, LLORET E et al.: Splenic marginal zone lymphoma: a distinctive type of low-grade B-cell lymphoma. A clinicopathological study of 13 cases. Am. J. Surg. Pathol. (1995) 19(10):1146-1157.
   PubMed Web of Science ®Google Scholar
• CONCONI A, MARTINELLI G, THIEBLEMONT C et al.: Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood (2003) 102(8):2741-2745.
   PubMed Web of Science ®Google Scholar
• KALPADAKIS C, PANGALIS GA, DIMOPOULOU MN et al.: Rituximab monotherapy is highly effective in splenic marginal zone lymphoma. Hematol. Oncol. (2007) 25(3):127-131.
   PubMed Web of Science ®Google Scholar
• LEHY MF, SEYMOUR JF, HICKS RJ, TURNER JH: Multicenter Phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma. J. Clin. Oncol. (2006) 24(27):4418-4425.
   PubMed Web of Science ®Google Scholar
• SWERDLOW SH, HABESHAW JA, MURRAY LJ, DHALIWAL HS, LISTER TA: Centrocytic lymphoma: a distinct clinicopathologic and immunologic entity. A multiparameter study of 18 cases at diagnosis and relapse. Am. J. Pathol. (1983) 113(2):181-197.
   PubMed Web of Science ®Google Scholar
• LARDELLI P, BOOKMAN MA, SUNDEEN J, LONGO DL, JAFFE ES: Lymphocytic lymphoma of intermediate differentiation. Morphologic and immunophenotypic spectrum and clinical correlations. Am. J. Surg. Pathol. (1990) 14(8):752-763.
   PubMed Web of Science ®Google Scholar
• HIDDEMANN W, UNTERHALT M, HERRMANN R et al.: Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German low-grade lymphoma study group. J. Clin. Oncol. (1998) 16(5):1922-1930.
   PubMed Web of Science ®Google Scholar
• VELDERS GA, KLUIN-NELEMANS JC, DEBOER CJ et al.: Mantle-cell lymphoma: a population-based clinical study. J. Clin. Oncol. (1996) 14(4):1269-1274.
   PubMed Web of Science ®Google Scholar
• ARATOFF LH, CONNORS JM, KLASA RJ, HORSMAN DE, GASCOYNE RD: Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood (1997) 89(6):2067-2078.
   PubMed Web of Science ®Google Scholar
• MAJLIS A, PUGH WC, RODRIGUEZ MA, BENEDICT WF, CABANILLAS F: Mantle cell lymphoma: correlation of clinical outcome and biologic features with three histologic variants. J. Clin. Oncol. (1997) 15(4):1664-1671.
   PubMed Web of Science ®Google Scholar
• GHIELMINI M, HSU SCHMITZ SF: The effect of rituximab on patients with follicular and mantle-cell lymphoma. Ann. Oncol. (2000) 11:S123-S126.
   PubMed Web of Science ®Google Scholar
• FORAN JM, ROHATINER A, CUNNINGHAM D et al.: European Phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J. Clin. Oncol. (2000) 18(2):317-324.
   PubMed Web of Science ®Google Scholar
• HOWARD OM, GRIBBEN JG, NEUBERG DS et al.: Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J. Clin. Oncol. (2002) 10(5):1288-1294.
   Google Scholar
• KAUFMANN H, RAFIQ K, WOEHRER S et al.: Brief report: antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood (2004) 104:2269-2271.
   PubMed Web of Science ®Google Scholar
• KHOURI IF, ROMAGUERA JE, KATARJIAN H et al.: Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J. Clin. Oncol. (1998) 16(12):3803-3809.
   PubMed Web of Science ®Google Scholar
• ROMAGUERA JE, FAYAD L, RODRIGUEZ MA et al.: Rituximab plus bypercvad (R-HCVAD) alternating with rituximab plus high-dose methotrexate-cytarabine (R-M/A) in untreated mantle cell lymphoma (MCL): prolonged follow-up confirms high rates of failure-free survival (FFS) and overall survival (OS). Blood (2004) 104 (Abstract).
   Google Scholar
• GALIMBERTI S, PALUMBO GA, CARACCIOLO F et al.: The efficacy of rituximab plus hyper-CVAD regimen in mantle cell lymphoma is independent of FCγRIIIa and FCγRIIa polymorphisms. J. Chemother. (2007) 19(3):315-321.
   PubMed Web of Science ®Google Scholar
• OKI Y, PRO B, DELPASSAND E et al.: A Phase II study of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) for treatment of patients with relapsed and refractory mantle cell lymphoma (MCL). Blood (2004) 104(11) (Abstract).
   Google Scholar
• ARMITAGE J, WEISENBURGER D: New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. J. Clin. Oncol. (1998) 16:2780.
   PubMed Web of Science ®Google Scholar
• ROSENWALD A, WRIGHT G, CHAN WC, CONNORS JM, CAMPO E, FISHER RI: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med. (2002) 346:1937-1947.
   PubMed Web of Science ®Google Scholar
• HANS CP, WEISENBURGER DD, GREINER TC et al.: Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood (2004) 103(1):275-282.
   PubMed Web of Science ®Google Scholar
• COIFFIER B, HAIOUN C, KETTERER N et al.: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter Phase II study. Blood (1998) 92(6):1927-1932.
   PubMed Web of Science ®Google Scholar
• COIFFIER B, LEPAGE E, BRIERE J et al.: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. (2002) 346(4):235-242.
   PubMed Web of Science ®Google Scholar
• MOUNIER N, BRIERE J, GISSELBRECHT C et al.: Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma. Blood (2003) 101(11):4279-4284.
   PubMed Web of Science ®Google Scholar
• HABERMANN TM, WELLER EA, MORRISON VA et al.: Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J. Clin. Oncol. (2006) 24(19):3121-3127.
   PubMed Web of Science ®Google Scholar
• PFREUNDSCHUH M, TRUMPER L, OSTERBORG A et al.: CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera international trial (MInT) group. Lancet Oncol. (2006) 7(5):379-391.
   PubMed Web of Science ®Google Scholar
• WILSON WH, FRANKEL SR, DRBOHLAV N et al.: Phase II study of dose-adjusted EPOCH-rituximab in untreated high risk large B-cell lymphomas. Proc. Am. Soc. Clin. Oncol. (2001) 20 (Abstract).
   Google Scholar
• KEWALRAMANI T, ZELENETZ A: Rituximab significantly increases the complete response rate in patients with relapsed or primary refractory DLBCL receiving ICE as second-line therapy (SLT). Blood (2001) 98:A346 (Abstract).
   Google Scholar
• HARTING R, VENUGOPAL P, GREGORY SA, O'BRIEN T, BOGDANOVA E: Efficacy and safety of rituximab combined with ESHAP chemotherapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Clin. Lymphoma Myeloma (2007) 7(6):406-412.
   PubMedGoogle Scholar
• GORDON LI, WITZIG TE, EMMANOUILIDES CE et al.: 90Y ibritumomab (zevalin) in aggressive non-Hodgkin's lymphoma: analysis of response and toxicity. Proc. Am. Soc. Clin. Oncol. (2002) 21 (Abstract).
   Google Scholar
• MORSCHHAUSER F, ILLIDGE T, HUGLO D et al.: Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood (2007) 110(1):54-58.
   PubMed Web of Science ®Google Scholar
• BYRD JC, MURGHY T, HOWARD RS et al.: Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toicity. J. Clin. Oncol. (2001) 19(8):2153-2164.
   PubMed Web of Science ®Google Scholar
• O'BRIEN S, KANTARJIAN H, BERAN M et al.: Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood (1993) 82(6):1695-1700.
   PubMed Web of Science ®Google Scholar
• WINKLER U, JENSEN M, MANZKE O, SCHULZ H, DIEHL V, ENGERT A: Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8). Blood (1999) 94:2217-2224.
   PubMed Web of Science ®Google Scholar
• O'BRIEN SM, KANTARJIAN H, THOMAS DA et al.: Rituximab dose-escalation trial in chronic lymphocytic leukemia. J. Clin. Oncol. (2001) 19(8):2165-2170.
   PubMed Web of Science ®Google Scholar
• KEATING MJ, O'BRIEN S, KANTARJIAN H et al.: Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood (1993) 81(11):2878-2884.
   PubMed Web of Science ®Google Scholar
• RAI KR, PETERSON BL, APPELBAUM FR et al.: Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N. Engl. J. Med. (2000) 343(24):1750-1757.
   PubMed Web of Science ®Google Scholar
• DIGAETANO N, XIAO Y, ERBA E et al.: Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br. J. Haematol. (2001) 114(4):800-8009.
   PubMed Web of Science ®Google Scholar
• WIERDA W, O'BRIEN S, WEN S et al.: Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J. Clin. Oncol. (2005) 23(18):4070-4078.
   PubMed Web of Science ®Google Scholar
• WIERDA WG, O'BRIEN S, FADERL S et al.: Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR), an active regimen for heavily treated patients with CLL. Blood (2006) 108 (Abstract).
   Google Scholar
• KEATING MJ, O'BRIEN S, ALBITAR M et al.: Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J. Clin. Oncol. (2005) 23(18):4079-4088.
   PubMed Web of Science ®Google Scholar
• TAM CS, O'BRIEN S, WIERDA W, LERNER H, KANTARJIAN H, KEATING MJ: Seventy percent of complete responders remain in continuous remission: five-year follow-up of 300 patients treated with fludarabine, cyclophosphamide, and rituximab (FCR) as initial therapy of CLL. J. Clin. Oncol. (2007) 25(18S) (Abstract).
   Google Scholar
• BYRD JC, PETERSON BL, MORRISON VA et al.: Randomized Phase II study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from cancer and leukemia group B. Blood (2003) 101(1):6-14.
   PubMed Web of Science ®Google Scholar
• TARHINI AA, LAND S, MEISNER D et al.: Early clinical and pharmocokinetic results of lower dose fludarabine and cyclophosphamide, and high dose rituximab (FCR-Lite) for patients with untreated chronic lymphocytic leukemia (CLL). Blood (2006) 108 (Abstract).
   Google Scholar
• KAY NE, GEYER SM, CALL TG et al.: Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood (2007) 109(2):405-411.
   PubMed Web of Science ®Google Scholar
• CHESON BD, BENNETT JM, GREVER M et al.: National cancer institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood (2007) 87(12):4990-4997.
   Google Scholar
• RAWSTRON AC, KENNEDY B, EVANS PA et al.: Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood (2001) 98(1):29-35.
   PubMed Web of Science ®Google Scholar
• MORENO C, VILLAMOR N, COLOMER D et al.: Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. Blood (2006) 107(11):4563-4569.
   PubMed Web of Science ®Google Scholar
• NABHAN C, COUTRE S, HILLMEN P: Minimal residual disease in chronic lymphocytic leukaemia: is it ready for primetime? Br. J. Haematol. (2007) 136(3):379-392.
   PubMed Web of Science ®Google Scholar
• GHIELMINI M, SCHMITZ SFH, COGLIATTI SB et al.: Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule. Blood (2004) 103(12):4416-4423.
   PubMed Web of Science ®Google Scholar
• WITZIG TE, VUKOV AM, HABERMANN TM et al.: Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a Phase II trial in the North central cancer treatment group. J. Clin. Oncol. (2005) 23(6):1103-1108.
   PubMed Web of Science ®Google Scholar
• FEUGIER P, HOOF AV, SEBBAN C et al.: Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d-Etude des Lymphomes de I'Adulte. J. Clin. Oncol. (2005) 23(18):4117-4126.
   PubMed Web of Science ®Google Scholar